NL-OMON51857Not yet recruitingNot Applicable
Evaluating the safety of shortened infusion times for different oncological immunotherapies; An observational prospective study - MINUTE
Isala Klinieken0 sites0 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 64 (—)
Inclusion Criteria
- •Starting, or already on treatment with monoclonal antibodies: nivolumab,
- •pembrolizumab and ipilimumab, durvalumab, atezolizumab, trastuzumab and
- •bevacizumab.
- •18 years and older.
- •No known history of increased susceptibility to immunological reactions.
- •Subject is able and willing to sign the Informed Consent Form prior to
- •screening evaluations.
Exclusion Criteria
- •Other research medication within 4 weeks of the start of the study.
- •Inclusion in medical research in which the administration of medication
- •should follow its stated times and dosages of infusions
- •Dosage deviates from standard protocol
Investigators
Similar Trials
Recruiting
Phase 4
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieOncologyInfusion ReactionNCT06031233Isala679
Not yet recruiting
Unknown
Short-term evaluation of the TRAX in knee replacementTotal knee arthroplastyMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disordersACTRN12624000192583Amplitude Australia PTY LTD50
Recruiting
Phase 3
Safety and Efficacy of abbreviated (12 hr) Magnesium Sulfate (MgSO4) therapy) vs. traditional 24 hrs therapy after delivery in Severe Preeclampsia: A Randomized Clinical TrialCTRI/2016/07/007076DirectorPGIMER Chandigarh240
Completed
Not Applicable
Efficacy of the shortening procedure time and safety under sufficient counter traction using Endoscopic Ring Thread Technique (ERTT)The inclusion criteria of this study's patients who satisfied the following expanded indication inclusion criteria for ESD according to the guidelines of the Japan Gastric Cancer Association (JGCA) were included. In differentiated gastric cancers, intramucosal carcinoma has no size restriction, whereas intramucosal carcinoma accompanied by ulcer scar and SM1 carcinoma (500 um from the muscularis mucosae) should be <30 mm. In undifferentiated carcinomas, intramucosal carcinoma should be <20 mm. Included patients consented to the study after receiving oral and written explanations.JPRN-UMIN000020158Kagawa university100
Recruiting
Unknown
Prolonged infusion time and colistin side effectsAcute kidney injury.Acute kidney failureIRCT20160713028901N6Esfahan University of Medical Sciences30